GLP-1 receptor agonist peptide

Exenatide

Exenatide is synthetic exendin-4. In vitro, exendin-4 was characterized as a GLP-1 receptor agonist. Its bibliography separates receptor recognition, cellular response and behavior of different formulations.

This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.

What changed from the reference

Write the evaluated material’s complete name. A shared family organizes a search but does not establish identity or result equivalence.

Which modification distinguishes the analog: sequence, terminus, conjugate or formulation?
Does the study compare both entities using the same assay?
Do the data separate molecular behavior from presentation effects?

Find readings for this question

Mechanism described in the literature

In fibroblasts engineered to express human GLP-1 receptors, exendin-4 induced cyclic AMP formation. This functional readout complemented binding experiments; receptor recognition and signal production were not equivalent measurements.

Other names in the literature

Exenatide
Synthetic exendin-4

Exendin-4 and its fragments

The 1993 receptor-expression study compared exendin-4 with exendin-(9-39). In vitro, the fragment behaved as an antagonist while the complete molecule produced an agonist response. Similar names can therefore conceal a central functional difference. References mentioning exendin require complete entity identification before results are attributed.

One ingredient in different formulations

DURATION-1 compared extended-release exenatide with another presentation of the same ingredient. It was a randomized, open-label investigation whose primary outcome was change in glycated hemoglobin. Its question concerned complete preparations: the common ingredient name neither removed the need for comparison nor made their exposure profiles universal exenatide properties.

What each evidence level adds

The cellular experiment identifies a ligand-receptor-signal relationship. DURATION-1 compares formulations in a defined clinical context. Neither replaces the other or describes every possible preparation. Molecular identity informs mechanism; formulation identity informs the comparative study.

Questions and answers

Is exendin-(9-39) another name for exenatide?

No. It is a distinct fragment with antagonist behavior in the cited cellular study.

Does extended release mean a different molecule?

Not necessarily. DURATION-1 compared different formulations sharing exenatide as their ingredient.